Dana Aftab Sells 1,162 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) EVP Dana Aftab sold 1,162 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares of the company's stock, valued at $15,666,873. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dana Aftab also recently made the following trade(s):

• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The stock was sold at an average price of $27.06, for a total transaction of $565,093.98.
• On Wednesday, August 7th, Dana Aftab sold 95,000 shares of Exelixis stock. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00.

Exelixis Price Performance

NASDAQ:EXEL traded up $0.92 on Friday, hitting $34.12. 4,537,149 shares of the company's stock were exchanged, compared to its average volume of 2,070,353. The firm has a 50-day moving average price of $27.13 and a 200-day moving average price of $24.29. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $34.45. The company has a market cap of $9.74 billion, a P/E ratio of 21.87, a price-to-earnings-growth ratio of 0.69 and a beta of 0.51.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same period in the previous year, the firm posted $0.10 EPS. The company's revenue for the quarter was up 14.3% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of analyst reports. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. Piper Sandler lifted their target price on shares of Exelixis from $33.00 to $36.00 and gave the stock an "overweight" rating in a report on Wednesday. BMO Capital Markets lifted their target price on shares of Exelixis from $29.00 to $36.00 and gave the stock an "outperform" rating in a report on Wednesday. HC Wainwright reissued a "buy" rating and issued a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Finally, Bank of America boosted their price target on shares of Exelixis from $30.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $31.44.

Institutional Investors Weigh In On Exelixis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter valued at about $30,000. Park Place Capital Corp bought a new stake in shares of Exelixis in the 2nd quarter valued at about $45,000. GAMMA Investing LLC raised its holdings in shares of Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC raised its holdings in shares of Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 1,746 shares during the period. Finally, Capital Performance Advisors LLP bought a new stake in shares of Exelixis in the 3rd quarter valued at about $61,000. 85.27% of the stock is owned by institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.